Lisa Schechner is a Partner and biotechnology investor at Commodore Capital who brings a distinct operator-investor background from Roivant Sciences, where she worked on the Investments team inside a biopharmaceutical company rather than at a traditional fund, concentrating on identifying, evaluating, licensing, and acquiring therapeutic development candidates. Her multi-disciplinary path combining wet science training in Molecular and Cellular Biology from Harvard College, management consulting experience at Bain & Company, and corporate biopharma investing gives her a differentiated perspective that spans basic biology, strategy, and therapeutic asset evaluation.